Explore

Rapid Read Rapid Read
Ultra-Processed Food Intake Linked to Higher Prostate Cancer Rates in U.S. Men

Ultra-Processed Food Intake Linked to Higher Prostate Cancer Rates in U.S. Men

A recent analysis of data from 17,024 U.S. men, published in The American Journal of Medicine, indicates that men who consume a larger proportion of their daily calories from ultra-processed foods (UPF) reported higher rates of prostate cancer. The study, conducted by researchers at Florida Atlantic University's Charles E. Schmidt College of Medicine, found that men in the higher-consumption groups showed adjusted prostate cancer rates that were 27% to 31% greater than those in the lowest-consumption group. For men in the highest consumption group alone, there was a possible 34% higher risk, though this did not reach statistical significance. The study utilized data from the National Health and Nutrition Examination Survey (2003-2023), classifying foods using the NOVA system and estimating UPF intake from two 24-hour dietary recalls. Ultra-processed foods, as defined by NOVA, include industrially formulated products like soft drinks, packaged snacks, sweetened cereals, and processed meats.
Rapid Read Rapid Read
OmicsLogic Inc. and ICSR Launch Integrated Cancer Genomics Training Program

OmicsLogic Inc. and ICSR Launch Integrated Cancer Genomics Training Program

OmicsLogic Inc., in collaboration with the Institute of Cancer and Stem Cell Research (ICSR), is launching a hands-on training program focused on integrated cancer biology and genomics. This program, scheduled from October 26 to November 3, 2026, aims to connect cancer cell biology, molecular experiments, and cancer genomics through a combined wet-lab and dry-lab learning experience. A key component of this training will involve the use of Variant Call Format (VCF) files, which are fundamental in cancer genomics. VCF files capture genetic variants such as single nucleotide polymorphisms (SNPs), insertions, deletions, and somatic mutations identified through sequencing data. By comparing tumor and normal samples, researchers can pinpoint cancer-driving mutations and uncover the molecular basis of the disease. These insights are crucial for identifying actionable biomarkers, predicting treatment responses, studying tumor evolution, and supporting precision oncology strategies. The program is designed for beg...
FactFable FactFable
Why PC build for streaming content (budget tier explained) Matters More Than Most Buyers Realize

Why PC build for streaming content (budget tier explained) Matters More Than Most Buyers Realize

Learn why a dedicated, budget-friendly PC for streaming is a smarter investment than most gamers and content creators think for improving quality.
Discover daily Discover daily
How Anchoring Bias Can Influence Even Experienced Professionals

How Anchoring Bias Can Influence Even Experienced Professionals

The anchoring effect, a cognitive bias where initial information influences subsequent judgments, is not merely a theoretical concept confined to p...
FactFable FactFable
Why DNS over HTTPS (DoH) Matters More in Cloud Environments

Why DNS over HTTPS (DoH) Matters More in Cloud Environments

Learn why DNS over HTTPS (DoH) is a critical security upgrade, especially for the unique privacy and security challenges of modern cloud environments.
Rapid Read Rapid Read
Merck and Moderna Announce Positive Phase 3 Trial Results for mRNA Cancer Vaccine in Melanoma Treatment

Merck and Moderna Announce Positive Phase 3 Trial Results for mRNA Cancer Vaccine in Melanoma Treatment

Merck and Moderna have reported positive results from a Phase 3 clinical trial (INTerpath-001) evaluating intismeran autogene, an individualized mRNA-based cancer vaccine, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda®). The trial focused on patients with high-risk melanoma whose tumors had been completely removed through surgery. The combination therapy significantly extended recurrence-free survival (the time patients went without their cancer returning) and improved distant metastasis-free survival (patients went longer without cancer returning in another part of the body) compared to Keytruda alone. This marks the first positive Phase 3 trial for an individualized neoantigen therapy and an mRNA-based cancer therapy. The individualized vaccine works by analyzing a patient's tumor to identify unique genetic mutations, called neoantigens, which are then encoded into mRNA to train the immune system to target these specific cancer cells. Keytruda, an immune checkpoint inhibitor...
Rapid Read Rapid Read
Global Study Reveals Significant Disparities in Colorectal Cancer Lifetime Risk

Global Study Reveals Significant Disparities in Colorectal Cancer Lifetime Risk

A new global assessment, the largest to date, has mapped the lifetime risk of developing and dying from colorectal cancer, revealing substantial disparities influenced by geography, national development levels, sex, and age. The study, published in Cancer Biology & Medicine, utilized GLOBOCAN 2022 and United Nations population estimates to determine that the global lifetime risk of developing colorectal cancer is approximately 2.7%, with a 1.4% risk of dying from it. Men generally face a slightly higher risk than women, and colon cancer incidence and mortality are consistently higher than rectal cancer. The findings highlight that incidence and mortality rates vary dramatically across countries, closely correlating with socioeconomic development, dietary changes, and the implementation of screening programs. High-income nations have seen declining mortality rates among older adults due to widespread colonoscopy use, which aids in detecting and removing precancerous lesions. Conversely, many low- and middle...
Rapid Read Rapid Read
University of Cincinnati Professor Designs Ergonomic Compression Garments for Breast Cancer Patients

University of Cincinnati Professor Designs Ergonomic Compression Garments for Breast Cancer Patients

Kristina Shin, an assistant professor of design at the University of Cincinnati's College of Design, Architecture, Art & Planning (DAAP), is leading research into the development of ergonomic compression garments for women with breast cancer-related lymphedema. This condition, which can cause swelling in the arms and surrounding areas, often follows breast cancer treatment. Shin's work focuses on creating garments that address not only therapeutic needs but also practical aspects such as fit, comfort, mobility, pressure distribution, ease of dressing, and appearance. Her interest in medical garment design began when she realized the difficulties breast cancer patients faced in finding comfortable, appropriate, and affordable post-mastectomy products. As an associate research member of the University of Cincinnati Cancer Center, Shin collaborates with clinicians and researchers, combining her expertise in intimate apparel and garment construction with medical knowledge to improve patients' daily experiences...
Rapid Read Rapid Read
10x Genomics Launches Atera Platform for Whole-Transcriptome Spatial Analysis

10x Genomics Launches Atera Platform for Whole-Transcriptome Spatial Analysis

10x Genomics has introduced Atera, a new spatial platform designed to measure the entire transcriptome with single-cell sensitivity and at a significantly larger scale. This launch marks a continued expansion of 10x Genomics' focus on spatial biology, following its earlier contributions to the single-cell revolution. According to Serge Saxonov, co-founder and CEO of 10x Genomics, customer shipments for the Atera platform are anticipated to commence later this year. Saxonov emphasizes that spatial biology is evolving beyond a niche research area, becoming a crucial method for integrating molecular, cellular, and tissue-level insights. The company's strategy involves developing advanced tools for biological measurement and addressing biological questions by working backward from them, rather than being solely driven by specific technologies. This approach has also led 10x Genomics into proteomics, with a belief that binder-based methods currently offer the most effective path to scalability. Furthermore, the...
Rapid Read Rapid Read
Moderna and Merck Announce Positive Phase 3 Trial Results for Personalized mRNA Cancer Vaccine in Melanoma

Moderna and Merck Announce Positive Phase 3 Trial Results for Personalized mRNA Cancer Vaccine in Melanoma

Moderna and Merck have announced positive results from a Phase 3 clinical trial for intismeran autogene, an individualized mRNA-based cancer vaccine, when combined with the immune checkpoint inhibitor pembrolizumab (Keytruda®). The trial focused on patients with high-risk melanoma whose tumors had been completely removed by surgery. The combination therapy significantly extended recurrence-free survival and distant metastasis-free survival compared to Keytruda alone. This marks the first positive Phase 3 trial for an individualized neoantigen therapy and an mRNA-based cancer therapy. The vaccine works by analyzing a patient's tumor to identify unique genetic mutations, called neoantigens, which are then encoded into a personalized mRNA vaccine. This vaccine instructs the immune system to target these specific cancer markers, while Keytruda helps sustain the immune response by blocking the PD-1 checkpoint.
Ventura County Star, Camarillo Ventura County Star, Camarillo
Polar outcomes for two friends | Woodburn

Polar outcomes for two friends | Woodburn

Bookend stories about two friends of mine, former colleagues both, one ends in heartbreak and the other with a mended heart.
Factlore Factlore
5 ways to use AI at work without letting your people skills erode

5 ways to use AI at work without letting your people skills erode

Discover five practical strategies to leverage artificial intelligence at work while strengthening your essential people skills for long-term career success.